FindTrial
Sign In

An in silico study comparing dose distributions between carbon ion radiotherapy and stereotactic body radiotherapy for hepatocellular carcinoma.

An in silico study comparing dose distributions between carbon ion radiotherapy and stereotactic body radiotherapy for hepatocellular carcinoma. - An in silico study comparing dose distributions between carbon ion radiotherapy and stereotactic body radiotherapy for hepatocellular carcinoma.

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000062024
Enrollment
40
Registered
2026-06-24
Start date
2026-06-24
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Sponsors

National Institutes for Quantum Science and Technology (QST)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma who underwent carbon-ion radiotherapy between January 2025 and December 2025 Patients with a maximum tumor diameter of <5 cm before treatment

Exclusion criteria

Exclusion criteria: Patients who opted out of the use of their information for this study

Design outcomes

Primary

MeasureTime frame
Dose to the normal liver in stereotactic body radiotherapy (SBRT) and carbon ion radiotherapy for hepatocellular carcinoma measuring under 5 cm.—

Secondary

MeasureTime frame
Dose to other normal tissues and residual liver volume in carbon ion radiotherapy and stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma measuring under 5 cm.—

Countries

Japan

Contacts

Public ContactMasaru Wakatsuki

National Institutes for Quantum Science and Technology (QST) QST Hospoital

wakatsuki.masaru@qst.go.jp043-206-3360

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026